hiv/aids: indinavir/ritonavir less effective than lopinavir/ritonavir as first-line haart

AIDS Weekly Plus HIV/AIDS: Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART Staff Medical Writers
May 24, 2004

-- Indinavir/ritonavir less effective than lopinavir/ritonavir as first-line HAART in HIV-1-infected patients. Immunovirological "outcomes and toxicities of HAART regimens, including Lopinavir (LPV)/ritonavir (r) and indinavir (IDV)/r," were compared in antiretroviral naive HIV-1 patients. Fifty-five and 52 patients, respectively, were selected to start LPV/r or IDV/r as first-line HAART, according to research in Italy. "Immunovirological and metabolic parameters were recorded at baseline and every 3 months as were side effects, AIDS-defining events and deaths. Demographic characteristics and NRTIs included in the regimens were comparable," wrote M. Bongiovanni and colleagues. "Both groups reached undetectable HIV-RNA plasma viremia" by the third month, which was maintained during follow-up. However, patients receiving IDV/r were less likely "to obtain virological success (RH: 0.46). Patients receiving IDV/r showed a greater increase of total cholesterol (P = 0.01). Three patients on LPV/r and 21 on IDV/r discontinued the drug for toxicity, leading to an 8.40 higher risk of discontinuation in the latter group," M. Bongiovanni and colleagues reported. Results indicate that IDV/r is "less effective and more toxic than LPV/RTV as first-line HAART," concluded the investigators. Bongiovanni and colleagues published the results of their research in Antiviral Research (Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects. Antiviral Res. 2004 Apr;62(1):53-6. For additional information, contact M. Bongiovanni, University Milan, L Sacco Hospital Vialba, Institute Infection Diseases & Trop Med, Via GB Grassi 74, I-20157 Milan, Italy. The publisher of the journal Antiviral Research can be contacted at: Elsevier Science BV, PO Box 211, 1000 AE Amsterdam, Netherlands. The information in this article comes under the major subject areas of AIDS and HIV, Antiretroviral, Pharmaceutical & Drug Development and Toxicity. This article was prepared by AIDS Weekly editors from staff and other reports. Reference Bongiovanni M, Bini T, Chiesa E, et al., "Lopinavir/ritonavir vs. indinavir/ritonavir in antiretroviral naive HIV-infected patients: immunovirological outcome and side effects", Antiviral Res. 2004 Apr;62(1):53-6 PubMED Related articles Search

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 UN: AIDS Deaths Down, Treatment Up in Africa Nairobi Solidarity Rally May 10 Proclaims: “No Retreat on AIDS – Treatment for All”CountyCare Offers Historic Opportunity to Improve Care for People with HIV AHF: Global AIDS Patients, Doctors Lobby Congress on PEPFAR Reauth International AIDS Advocates Demand China Give $1 Billion to Global Fund Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa GLOBAL: HIV Outcomes Could Improve by Integrating Treatment of Comorbid Mental Illness
Copyright © 2004 -AIDS Weekly Plus, Publisher. All rights reserved to Charles Henderson, Publisher. Permission to reproduce granted to AEGIS by Charles W. Henderson. Authorization to reproduce for personal use granted granted by C. W. Henderson, Publisher, provided that the fee of US$4.50 per copy, per page is paid directly to the Copyright Clearance Center, 27 Congress Street, Salem, Massachusetts 01970, USA. Published by Charles Henderson, Publisher. Editorial & Publishing Office: P.O. Box 5528, Atlanta, GA 30307-0528 / Telephone: (800) 633- 4931; Subscription Office: P.O. Box 830409, Birmingham, AL 35283-0409 / FAX:(205) 995-1588 Visit AIDS WEEKLY PLUS. Information in this article was accurate in May 24, 2004. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.